Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

endpoints include duration of response, progression-free survival and overall survival.

Owen A. O'Connor, MD, PhD, Director, Lymphoid Development & Malignancy Program and Chief, Lymphoma Service, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, is the international study chair.

In accordance with the PROPEL study design, in January 2007, the DMC completed an interim analysis of safety data based on the first 10 patients enrolled to the study who completed at least one cycle of treatment with PDX, and recommended that the trial continue per the protocol. Also in accordance with the study design, in September 2007, an interim analysis of patient response and safety data was conducted based on the first 35 patients enrolled to the study who completed at least one cycle of treatment with PDX. The results of the interim analysis of patient response data exceeded the pre-specified threshold for continuation of the trial, which required a minimum of four responses (complete or partial) out of the first 35 evaluable patients, as determined by independent oncology review. In addition, the DMC identified no major safety concerns and recommended that the trial continue per the protocol.

The PROPEL trial is being conducted under an agreement with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process. The SPA process allows for FDA evaluation of a clinical trial protocol intended to form the primary basis of an efficacy claim in support of an NDA, and provides an agreement that the study design, including trial size, clinical endpoints and/or data analyses are acceptable to the FDA. The FDA granted orphan drug designation to PDX for the treatment of T-cell lymphoma in July 2006 and granted fast track designation to PDX for the treatment of patients with T-cell lymphoma in September 2006. In April 2007, the Commission of the European Communities, with a favorable opinion of the Comm
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... DIEGO and BOSTON , ... leader in instrument development, custom automation, and contract manufacturing, ... of the Nanopatch™ needle-free drug delivery technology, have been ... development of the Nanopatch Jet Coating Instrument , ... delivery research and product development.  The award was announced ...
(Date:5/29/2015)... SAN DIEGO , May 29, 2015 /PRNewswire/ ... single cell sequencing data, from metastatic castrate resistant ... of the American Society for Clinical Oncology. This ... no cell left behind™ platform to ... study revealed that late stage patients have heterogeneous ...
(Date:5/28/2015)... Lilly and Company (NYSE: LLY ) announced today the ... up to $1.6 billion aggregate principal amount of certain of ... tendered, and did not validly withdraw, their notes on or ... time, on May 27, 2015 (the early tender date), and ... receive the total consideration. The total consideration for each series ...
Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... 2011 The Rottenstein Law Group, which represents clients with ... manufactured and sold by DePuy Orthopaedics, is fully in support ... of metal-on-metal joint implants. At a new set ... U.S. Food and Drug Administration states the following: ...
... VILLAGE, Nev., March 7, 2011   PDL BioPharma, ... guidance for the first quarter ending March 31, 2011 of ... million for the first quarter of 2010, an expected 34 ... the $10 million settlement received from UCB Pharma S.A. (UCB) ...
Cached Medicine Technology:Rottenstein Law Group Applauds New Efforts of U.S. FDA to Look More Carefully at Metal-on-Metal Implants After DePuy Recall 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 3PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 4
(Date:5/29/2015)... May 29, 2015 Johnson & ... a confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement ... due to his use of the antipsychotic medication. ... selected for the third bellwether trial to involve ... litigation underway in Pennsylvania’s Philadelphia Court of Common ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The ... the graduates of its Advanced Training Program (ATP) ... who fill roles in their health care organization ... theory and methodology of continuous quality improvement in ... sister-program to Dr. Brent James’ internationally recognized Advanced ...
(Date:5/29/2015)... A group of doctors have discovered “The Cure ... to teach this “new math” to children in early childhood ... by the recent implementation of Common Core Math in classrooms ... Core is now a reality in children’s classrooms in 44 ... seeking ways to improve common core math training for their ...
(Date:5/29/2015)... 2015 World Patent Marketing, a vertically ... it has signed a 10 year licensing agreement for ... to let people learn about any topic and get ... "This is an exciting day for World Patent Marketing ... Cooper, CEO and Creative Director of World Patent Marketing, ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 ... Utah, recently partnered with Stratus Video ... which will facilitate better communication and timely ... (LEP) and hearing loss. Stratus’ video remote ... in-house translators, enabling staff to quickly access ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:Doctors Discover a Cure for the Common Core 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4
... , ... ... ... , ...
... ... ... ... ...
... MS Awareness Week March 8-14 is the ... someone is newly diagnosed every hour of every day. Supported by a Congressional resolution, this year ... world free of MS! , ... March 8, 2010 -- MS Awareness Week March 8-14 is the time for the nation ...
... , ... ... ... ...
... ... pictures that are better than anything that’s come before. With the new technology they’ve developed, ... in the heart and the major arteries around it. , ... Madison, WI (PRWEB) March 8, 2010 -- What does the ...
... ... announced today they have been named as the preferred distributor of Gendron bariatric care ... Gendron bariatric care medical equipment to healthcare professionals who wish to purchase or lease. ... Issaquah, WA. ...
Cached Medicine News:Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 2Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 3Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 4Health News:World Cocoa Foundation Launches Cocoa Livelihoods Program in Nigeria 5Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 2Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 3Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 4Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 5Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 6Health News:Beverage Industry Delivers On Commitment to Remove Regular Soft Drinks In Schools, Driving 88% Decline In Calories 7Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 2Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 3Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 4Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 5Health News:MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010, 6Health News:I'm Not Crazy...I'm Just Not You 2Health News:I'm Not Crazy...I'm Just Not You 3Health News:I'm Not Crazy...I'm Just Not You 4Health News:I'm Not Crazy...I'm Just Not You 5Health News:I'm Not Crazy...I'm Just Not You 6Health News:Heart Aflutter? Remarkable New Images Show What it Looks Like in 4-D 2Health News:Heart Aflutter? Remarkable New Images Show What it Looks Like in 4-D 3Health News:QuickMedical Launches New Line of Medical Equipment for Bariatric Care 2Health News:QuickMedical Launches New Line of Medical Equipment for Bariatric Care 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: